Psoriatic arthritis. When the heterogeneity requires normality

Area of Science:

• Rheumatology
• Immunology
• Dermatology

Background:

• Psoriatic arthritis (PsA) exhibits diverse clinical manifestations, including enthesopathy, dactylitis, osteitis, and axial involvement, complicating its definition and classification.
• Diagnostic challenges arise from radiological changes in asymptomatic psoriasis patients and normal acute-phase reactants (erythrocyte sedimentation rate, C-reactive protein).
• These diagnostic and classification complexities have historically impacted the reliability of epidemiological studies and treatment efficacy assessments.

Discussion:

• Traditional treatments like NSAIDs, steroids, and DMARDs offer limited efficacy in addressing the multifaceted nature of PsA and its radiographic progression.
• The heterogeneity of PsA expression and diagnostic hurdles contribute to suboptimal responses to conventional therapies.
• Neglect of specific PsA features and diagnostic nuances may explain the unsatisfactory outcomes with traditional drugs.

Key Insights:

• Anti-TNF agents have demonstrated a significant ability to impact multiple facets of psoriatic arthritis.
• These biologic therapies effectively slow radiographic progression and improve patient quality of life.
• The therapeutic benefits of anti-TNF agents appear to be achieved with a favorable cost-effectiveness ratio.

Outlook:

• Further research into the underlying mechanisms of PsA heterogeneity is warranted.
• Optimizing diagnostic criteria and incorporating advanced imaging may improve patient stratification.
• Continued investigation into the long-term efficacy and safety of anti-TNF agents and other targeted therapies is crucial for advancing PsA management.